Wistar Institute will use 3D-printed lung models made by Allevi for coronavirus research - Technical.ly Philly

Growth

Jun. 29, 2020 1:48 pm

Wistar Institute will use 3D-printed lung models made by Allevi for coronavirus research

The Pennovation-based company's bioprinting platform will create the models for scientists at the University City biomedical research center to study the virus behind COVID-19.
An Allevi bioprinter at Memorial Sloan Kettering Cancer Center in New York City.

An Allevi bioprinter at Memorial Sloan Kettering Cancer Center in New York City.

(Photo via twitter.com/McLarney_)

Pennovation-based life sciences technology company Allevi is partnering with University City-based biomedical research center The Wistar Institute to use 3D printing to learn about COVID-19.

COVID-19 is an acute respiratory illness and has taken more than 500,000 lives worldwide. Allevi’s patented 3D bioprinting platform will create 3D models of lungs for Wistar scientists to use to study the virus behind COVID-19, SARS-CoV-2, in order to “investigate the mechanisms deployed by this pathogen to infect humans and identify potential ways in which it may be blocked,” according to a press release.

Earlier this month, Wistar announced that it had seen “positive results” from its preclinical testing of a COVID-19 DNA vaccine it developed with Plymouth Meeting’s Inovio Pharmaceuticals.

Allevi VP of Life Sciences Taciana Pereira, who is also co-principal investigator in this plan, is optimistic about the project’s efforts to assist COVID-19 research.

“We are accompanying the spectacular work from our peers in the scientific community and have identified tremendous potential for our platform to enable COVID-19 research in a much faster, yet physiologically relevant manner,” she said in a statement. “We believe that scientists from all areas need to unite now to solve this crisis.”

David B. Weiner, Ph.D. is the executive VP and director of Wistar’s Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Professor in Cancer Research and will be the project lead. He also leads the group developing the DNA vaccine with Inovio.

“We have been advancing scientific investigations aimed at the treatment and prevention of COVID-19, and we believe that Allevi’s innovative approach is an exciting modality to gain unique insights into the inner workings of the novel coronavirus,” he said.

Advertisement

Since its founding in 2014, Allevi has raised $3.8 million through seven rounds of funding, according to Crunchbase. Allevi was originally known as BioBots, a bioprinting company that began making a stronger push for the software space with its 2017 rebrand. It reports that its technology is used in 350 labs across 40 countries. In May 2019, Allevi was one of 11 companies and leaders to receive a Philadelphia Alliance for Capital and Technologies award for being a top emerging healthcare company.

The Wistar Institute announced in April that it will open an 8,000-square-foot space at 3.0 University Place at 41st and Market streets to support collaboration among STEM researchers, called the Wistar Discovery Center, while maintaining its HQ at 36th and Spruce streets.

Companies: BioBots
-30-
CONTRIBUTE TO THE
JOURNALISM FUND

Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

Sign-up for daily news updates from Technical.ly Philadelphia

Do NOT follow this link or you will be banned from the site!